These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10715410)

  • 1. Oral administration of alloantigen plus nondepleting anti-CD4 monoclonal antibody induces indefinite prolongation of fully allogeneic cardiac allografts.
    Niimi M; Ikeda Y; Shirasugi N; Shatari T; Takami H; Kodaira S; Matsumoto K; Hamano K; Esato K; Hara M; Wood KJ
    Transplant Proc; 2000 Mar; 32(2):259. PubMed ID: 10715410
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral delivery of alloantigen combined with non-depleting anti-CD4 monoclonal antibody induces indefinite survival of cardiac allografts and generates CD4(+) regulatory T cells.
    Niimi M; Ikeda Y; Shirasugi N; Shatari T; Takami H; Kodaira S; Matsumoto K; Hamano K; Esato K; Hara M; Wood KJ
    Transplant Proc; 2000 Nov; 32(7):2035. PubMed ID: 11120054
    [No Abstract]   [Full Text] [Related]  

  • 3. Oral administration of alloantigen induces indefinite prolongation of MHC mismatched cardiac allografts.
    Niimi M; Morris PJ; Wood KJ
    Transplant Proc; 1999; 31(1-2):892. PubMed ID: 10083392
    [No Abstract]   [Full Text] [Related]  

  • 4. Induction of operational tolerance and generation of regulatory cells after intratracheal delivery of alloantigen combined with nondepleting anti-CD4 monoclonal antibody.
    Aramaki O; Shirasugi N; Akiyama Y; Takayama T; Shimazu M; Kitajima M; Ikeda Y; Niimi M
    Transplantation; 2003 Nov; 76(9):1305-14. PubMed ID: 14627908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nondepleting anti-CD4 monoclonal antibody enhances the ability of oral alloantigen delivery to induce indefinite survival of cardiac allografts: oral tolerance to alloantigen.
    Niimi M; Witzke O; Bushell A; Hara M; Morris PJ; Wood KJ
    Transplantation; 2000 Nov; 70(10):1524-8. PubMed ID: 11118100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of donor specific transplantation tolerance to cardiac allografts following treatment with nondepleting (RIB 5/2) or depleting (OX-38) anti-CD4 mAb plus intrathymic or intravenous donor alloantigen.
    Arima T; Lehmann M; Flye MW
    Transplantation; 1997 Jan; 63(2):284-92. PubMed ID: 9020332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of donor-specific unresponsiveness to rat allografts by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) plus donor antigen.
    Motoyama K; Lehmann M; Flye MW
    Transplant Proc; 1999; 31(1-2):1237-8. PubMed ID: 10083552
    [No Abstract]   [Full Text] [Related]  

  • 8. Survival of fully allogeneic cardiac allografts induced by delivery of alloantigen via respiratory mucosa is abrogated by blockade of the B7 pathway.
    Shirasugi N; Matsumoto S; Hamano K; Esato K; Matsumoto K; Bashuda H; Yagita H; Okumura K; Ikeda Y; Takami H; Kodaira S; Niimi M
    Transplant Proc; 2000 Nov; 32(7):2034. PubMed ID: 11120053
    [No Abstract]   [Full Text] [Related]  

  • 9. Administration of anti-CD4 monoclonal antibody with intrathymic injection of alloantigen results in rat cardiac allograft tolerance.
    Arima T; Goss JA; Walp LA; Flye MW
    Surgery; 1995 Aug; 118(2):265-72; discussion 272-3. PubMed ID: 7638743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerance to heart and kidney grafts induced by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) versus depleting anti-CD4 monoclonal antibody (OX-38) with donor antigen administration.
    Motoyama K; Arima T; Lehmann M; Flye MW
    Surgery; 1997 Aug; 122(2):213-9; discussion 219-20. PubMed ID: 9288125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The kinetics of tolerance induction by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) plus intravenous donor alloantigen administration.
    Motoyama K; Arima T; Yu S; Lehmann M; Flye MW
    Transplantation; 2000 Jan; 69(2):285-93. PubMed ID: 10670640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The thymus is essential for the development of operational tolerance induced by donor-specific transfusion plus anti-CD4 monoclonal antibody.
    Niimi M; Ikeda Y; Shirasugi N; Shatari T; Takami H; Kodaira S; Matsumoto K; Hamano K; Esato K; Wood KJ
    Transplant Proc; 2000 Nov; 32(7):2067. PubMed ID: 11120069
    [No Abstract]   [Full Text] [Related]  

  • 13. Indefinite survival of fully allogeneic cardiac grafts induced by antigen delivery through the alimentary tract.
    Niimi M; Ikeda Y; Kan S; Shirasugi N; Hamano K
    J Thorac Cardiovasc Surg; 2001 Sep; 122(3):629-30. PubMed ID: 11547327
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunogenic (MHC class II+) cells are able to induce unresponsiveness when delivered with anti-CD4 monoclonal antibody.
    Niimi M; Morris PJ; Wood KJ
    Transplant Proc; 1998 Aug; 30(5):2450. PubMed ID: 9723533
    [No Abstract]   [Full Text] [Related]  

  • 15. Intrathymic inoculation of donor B cells induced indefinite prolongation of fully allogeneic cardiac grafts but not islet or skin grafts.
    Niimi M; Ikeda Y; Shirasugi N; Shatari T; Takami H; Kodaira S; Matsumoto K; Hamano K; Esato K; Wood KJ
    Transplant Proc; 2000 Nov; 32(7):2020. PubMed ID: 11120047
    [No Abstract]   [Full Text] [Related]  

  • 16. Pretransplant administration of a single donor class I major histocompatibility complex molecule is sufficient for the indefinite survival of fully allogeneic cardiac allografts: evidence for linked epitope suppression.
    Wong W; Morris PJ; Wood KJ
    Transplantation; 1997 May; 63(10):1490-4. PubMed ID: 9175815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of thymus to maintain operational tolerance to fully allogeneic cardiac grafts.
    Niimi M; Shirasugi N; Ikeda Y; Kan S; Takami H; Hamano K
    Ann Thorac Surg; 2001 Sep; 72(3):735-9. PubMed ID: 11565650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocyte changes associated with prolongation of cardiac allograft survival in adult mice using anti-CD4 monoclonal antibody.
    Pearson TC; Bushell AR; Darby CR; West LJ; Morris PJ; Wood KJ
    Clin Exp Immunol; 1993 May; 92(2):211-7. PubMed ID: 8097975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B7/CTLA4 pathway is essential for generating regulatory cells after intratracheal delivery of alloantigen in mice.
    Akiyama Y; Shirasugi N; Uchida N; Matsumoto K; Kitajima M; Bashuda H; Yagita H; Okumura K; Aramaki O; Niimi M
    Transplantation; 2002 Sep; 74(5):732-8. PubMed ID: 12352894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD25+ regulatory cells generated by intratracheal delivery of alloantigen.
    Akiyama Y; Shibutani S; Matsumoto K; Kitajima M; Aramaki O; Yokoyama T; Kan S; Ikeda Y; Shirasugi N; Niimi M
    Transplant Proc; 2002 Aug; 34(5):1443-4. PubMed ID: 12176431
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.